Medication info
Janumax M Tablet 50/1000 mg

Janumax M Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
Dark red oval film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 120 tablets/bottle
Approval status
Active

MFDS item code 202200899 · Approved 2022.03.02 · Insurance code 644004600

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to help control blood glucose in patients with type 2 diabetes using sitagliptin and metformin in combination. It is more effective when taken alongside dietary management and exercise therapy and helps to reliably maintain blood sugar levels. This contributes to the improvement of diabetes symptoms and the prevention of complications.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains both sitagliptin and metformin and is used in the treatment of diabetes. Firstly, an allergic reaction may occur when taking this medication, so if symptoms such as skin rash, hives, or breathing difficulties occur, you should immediately stop taking it and consult a doctor. Additionally, serious side effects including acute pancreatitis, which is inflammation of the pancreas, have been reported, so if symptoms of pancreatitis such as abdominal pain, nausea, or vomiting occur while taking it, you should inform your healthcare provider immediately. The metformin component of this medication can cause lactic acidosis, a rare but serious metabolic complication; therefore, if symptoms such as severe fatigue, muscle pain, shortness of breath, or abdominal pain occur, you should immediately stop taking it and go to the hospital. Patients with impaired kidney function, severe infection, dehydration, acute heart failure, or acute myocardial infarction should not take this medication, and it should be temporarily stopped before and after surgery or before and after examinations using iodinated contrast agents. While taking this medication, you should undergo regular kidney function and blood tests, especially elderly patients or those with reduced kidney function should exercise extra caution. This medication has a risk of hypoglycemia, so care should be taken when meals are skipped, irregular eating occurs, or excessive exercise is undertaken, and dosage adjustments may be necessary when taken with insulin or sulfonylurea drugs as hypoglycemic symptoms may be more pronounced. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking while on this medication. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication, and safety has not been established for use in children under 18 years of age. If sudden skin disorders, severe joint pain, or blistering skin lesions occur during treatment with this medication, it should be reported to a physician immediately. Finally, while taking this medication, regular blood sugar tests and ongoing health management according to the doctor's instructions are essential.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 27 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dermatitis
  • anorexia
  • weight loss
  • rash
  • urticaria
  • skin vasculitis
  • elevated liver enzymes
  • acute renal failure
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air exposure, ideally at room temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

Dark red oval film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 120 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.